Navigating the Potential of Ketamine in Depression Treatment

Researchers in New Zealand caution against a rapid large-scale increase in the use of ketamine as a treatment for depression, despite its potential benefits for treatment-resistant depression. While ketamine shows significant short-term improvements, it is associated with high relapse rates and potential misuse. Careful patient selection, close monitoring, and robust support structures are recommended for its controlled use. The Royal Australian and New Zealand College of Psychiatrists suggests restricting its use to treatment-resistant depression and ensuring familiarity with the drug among clinicians.